Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KTOV.TA
- Price
- 4.80
- Stock movement down
- -0.30 (-5.88%)
- Company name
- Purple Biotech Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology & Medical Research
- Market cap
- 826.11M
- Ent value
- 792.75M
- Price/Sales
- -
- Price/Book
- 14.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -81.18%
- 3 year return
- -62.08%
- 5 year return
- -53.16%
- 10 year return
- -63.60%
Last updated: 2025-04-12
DIVIDENDS
KTOV.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 14.71 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 172.11M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -3.59M |
| Net income (TTM) | -3.27M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 62.99M |
| Net receivables | 1.00M |
| Total current assets | 65.16M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 85.78M |
| Accounts payable | 2.96M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 29.38M |
| Total liabilities | 29.64M |
| Shareholder's equity | 56.15M |
| Net tangible assets | 35.26M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.95M |
| Capital expenditures (TTM) | 3.00K |
| Free cash flow (TTM) | -7.96M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -5.83% |
| Return on Assets | -3.82% |
| Return on Invested Capital | -5.83% |
| Cash Return on Invested Capital | -14.17% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.00 |
| Daily high | 5.10 |
| Daily low | 4.70 |
| Daily Volume | 268K |
| All-time high | 25999999997.40 |
| 1y analyst estimate | - |
| Beta | 2.04 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | 30 Oct 2012 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KTOV.TA | S&P500 | |
| Current price drop from All-time high | -100.00% | -14.41% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -63.95% | -11.07% |
| Avg time to new high | 3 days | 12 days |
| Max time to new high | 6326 days | 1805 days |
COMPANY DETAILS
Marketcap
826.11M
Marketcap category
Small-cap
Description
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.
Employees
9
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found